Overview

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

Status:
Unknown status
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for which there are no currently accepted therapies.
Phase:
Phase 1
Details
Lead Sponsor:
Metronome Therapeutics
Treatments:
Vinblastine
Vinorelbine